The newborn jaundice treatment market is projected to grow at a 4.1% CAGR from 2026 to 2036, with overhead phototherapy units accounting for 55.7% of market share in 2026.

October 23, 2026 The global newborn jaundice treatment market is projected to reach USD 6.4 billion by 2036, rising from USD 4.2 billion in 2026, according to Fact.MR analysis updated February 26, 2026. The forecast represents an absolute dollar opportunity of USD 2.2 billion over the decade, supported by demand for phototherapy systems, improved early diagnosis, and expanding access to neonatal healthcare. Hospitals are expected to remain the primary treatment setting, accounting for 79.3% of market share in 2026.

The findings highlight a practical challenge for healthcare providers: delivering timely, appropriate treatment while managing costs and differences in healthcare access. Newborn jaundice, associated with elevated bilirubin levels, requires careful assessment and treatment when clinically indicated. Advances in phototherapy equipment and bilirubin monitoring are shaping purchasing decisions as healthcare systems strengthen newborn screening and treatment practices.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=14397

Newborn Jaundice Treatment Market Growth Reflects Changing Clinical Needs

Fact.MR estimates that the market was valued at USD 4 billion in 2025. The projected increase to USD 4.2 billion in 2026 establishes the baseline for further expansion through 2036, when the market is forecast to reach USD 6.4 billion at a compound annual growth rate (CAGR) of 4.1%.

The newborn jaundice treatment market covers medical therapies and technologies used to manage jaundice in newborns. These include phototherapy devices, bilirubin-lowering medications, and diagnostic aids used in hospitals, clinics, and neonatal care units.

Market fact block: Fact.MR is a market research and consulting firm that provides industry analysis, market sizing, and long-term revenue forecasts to support business planning.

The report combines primary interviews with neonatologists, pediatric clinicians, and medical device specialists with desk research using clinical reports, healthcare databases, and industry publications. Fact.MR applies a hybrid forecasting model that combines top-down disease prevalence estimates with bottom-up treatment adoption and revenue data. Expert review and comparisons with recent treatment, usage, and production statistics support the validation process.

Phototherapy Devices and Hospitals Lead Market Demand

Overhead phototherapy units are projected to hold 55.7% of the newborn jaundice treatment market in 2026. Their position reflects established use in hospitals, where equipment must deliver appropriate light intensity across a broad treatment area. These systems are used to help reduce bilirubin levels in newborns who require phototherapy.

LED-based phototherapy systems and portable treatment devices are also attracting attention as manufacturers develop equipment intended to improve treatment delivery and patient comfort. Fiberoptic blankets represent another option in the wider treatment landscape. Adoption will depend on clinical requirements, equipment costs, and the care setting.

Hospitals are expected to account for 79.3% of market share in 2026. Specialized neonatal units, trained healthcare professionals, and access to phototherapy equipment support their leading position. Hospitals also provide settings for bilirubin assessment and monitoring when newborns require closer clinical supervision.

The distinction between the two leading segments is important: overhead phototherapy units represent a device category, while hospitals represent an application setting. Together, the figures illustrate how equipment demand and treatment delivery are connected.

China and India Record the Fastest Country Growth

China is projected to record the highest growth among the seven countries assessed, with a CAGR of 5.5% through 2036. Fact.MR attributes this outlook to the country's large population, expanding healthcare infrastructure, and improving access to neonatal care.

India follows at 5.1%, supported by increasing awareness of newborn jaundice and improvements in neonatal healthcare services. The forecast places both Asian markets ahead of Germany, where demand is projected to grow at 4.7% annually.

Brazil is expected to record a 4.3% CAGR, reflecting healthcare investment and growing awareness of newborn jaundice treatment. The United States follows at 3.9%, while the United Kingdom is projected to grow at 3.5%. Japan records the lowest forecast growth among the countries listed, at 3.1%, reflecting its mature market and established healthcare system.

These country-level forecasts give equipment manufacturers and healthcare suppliers a basis for comparing potential demand. However, market growth alone does not establish affordability or access for individual families and healthcare facilities.

Treatment Costs and Access Remain Key Constraints

The cost of advanced phototherapy devices and their ongoing maintenance may limit adoption in price-sensitive markets. Differences in healthcare infrastructure can also restrict access to appropriate treatment in underserved regions.

For manufacturers, developing more affordable and compact equipment could help address budget constraints. Expanding distribution and service capabilities in emerging markets may also support adoption, particularly where neonatal healthcare infrastructure is improving.

Clinical guidelines remain another influence on demand. In March 2025, the Canadian Paediatric Society published an updated position statement on detecting and managing hyperbilirubinemia in newborn infants. The report also identifies Drägerwerk AG & Co. KGaA's March 2025 expansion of its neonatal portfolio through BiliPredics, an FDA-registered AI software solution designed to forecast individual bilirubin progression up to 60 hours in advance.

These developments illustrate activity across treatment and monitoring technologies. They do not, by themselves, establish a direct causal relationship with the market's projected revenue growth.

Competition Focuses on Treatment and Monitoring Technologies

The competitive landscape includes GE HealthCare Technologies Inc., Koninklijke Philips N.V., Drägerwerk AG & Co. KGaA, Natus Medical Incorporated, and Bilimetrix Inc. Other companies identified in the report include Atom Medical Corporation, Nice Neotech Medical Systems Pvt. Ltd., TheraB Medical, Phoenix Medical Systems Pvt. Ltd., and Ibis Medical Ltd.

Their offerings span phototherapy equipment, bilirubin measurement, and neonatal monitoring. Product development, pricing, and access to healthcare markets are relevant considerations as providers evaluate treatment technologies.

The full Fact.MR newborn jaundice treatment market report] provides further analysis of market segments, country forecasts, competitive positioning, and the methodology used to estimate demand. For clinical context, readers can also consult the [LINK: World Health Organization's newborn health resources.

View Related Reports :

https://social.mytamam.com/blogs/1/Foodgrade-Recycled-Polymers-Market-Food-Grade-Recycled-Plastics-Recycled-Polymers

https://ayushjadhavblogs.blogspot.com/2026/10/china-pcr-packaging-market-forecast-to.html

https://ayushjad.mataroa.blog/blog/india-leads-growth-prospects-in-the-aquaculture-fungal-infection-treatment-market

https://sohomoy.com/blogs/69940/Medical-Tourism-Market-to-Reach-USD-1-000-2-Billion

About Fact.MR

Fact.MR is a market research and consulting firm that provides market intelligence, industry analysis, and forecasts across sectors. Its research supports businesses in evaluating market size, regional opportunities, competitive dynamics, and potential changes in demand.